Ocular Safety of GLP‐1 Receptor Agonists: A Comprehensive Review
Obesity Science & Practice · 2026-12 · 12 (6)
DOI: 10.1002/osp4.70205 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity Science & Practice, online erschienen am 15.11.2026. Verfasst von Elias Hanna und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Medical Sciences University of Balamand El Koura Lebanon. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) provide substantial glycemic and cardiometabolic benefits, but concerns regarding diabetic retinopathy (DR) progression and nonarteritic anterior ischemic optic neuropathy (NAION) have raised questions about their ocular safety. This review critically evaluates current evidence and its clinical implications.
Methods
A structured literature search of PubMed/MEDLINE, Embase, and Scopus was conducted from inception through July 2026. Evidence from randomized trials, observational studies, meta‐analyses, pharmacovigilance investigations, clinical guidelines, and regulatory documents was narratively synthesized.
Results
In SUSTAIN‐6, semaglutide increased DR complications compared with placebo (3.0% vs. 1.8%; hazard ratio 1.76, 95% confidence interval 1.11–2.78), predominantly among patients with pre‐existing retinopathy and substantial early glycemic improvement. However, subsequent trials and meta‐analyses did not establish a consistent class‐wide increase in retinopathy risk. Early worsening appears more closely associated with rapid glycemic reduction than with established direct retinal toxicity. Observational and pharmacovigilance studies have identified a potential association between GLP‐1 RAs and NAION, although conflicting findings, limited event numbers, and residual confounding preclude definitive causal inference.
Conclusions
Current evidence favors individualized ocular risk assessment and targeted ophthalmologic surveillance rather than routine avoidance of GLP‐1 RAs. Patients with established retinopathy warrant particular attention during treatment initiation. Prospective studies incorporating standardized ophthalmologic outcomes are essential to clarify unresolved safety signals and optimize clinical monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine and Medical Sciences University of Balamand El Koura Lebanon.
- Department of Endocrinology YAS Healthcare Medical Center Abu Dhabi UAE.
ORCID-Profile: Elias Hanna, Carl Karam, Saad Aad, Ali Ali, Joe Farah, Anne-Sophie Azzi
Zitieren
APA
Hanna, E., Karam, C., Aad, S., Ali, A., Farah, J., & Azzi, A. S. (2026). Ocular Safety of GLP‐1 Receptor Agonists: A Comprehensive Review. Obesity Science & Practice, 12(6). https://doi.org/10.1002/osp4.70205
Vancouver
Hanna E, Karam C, Aad S, Ali A, Farah J, Azzi AS. Ocular Safety of GLP‐1 Receptor Agonists: A Comprehensive Review. Obesity Science & Practice. 2026;12(6). doi:10.1002/osp4.70205
BibTeX
@article{Hanna2026,
author = {Hanna, Elias and Karam, Carl and Aad, Saad and Ali, Ali and Farah, Joe and Azzi, Anne-Sophie},
title = {Ocular Safety of GLP‐1 Receptor Agonists: A Comprehensive Review},
journal = {Obesity Science & Practice},
year = {2026},
volume = {12},
number = {6},
doi = {10.1002/osp4.70205}
}
EUVIMED